ReviewNeuro-oncology2026
Attract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas.
Review in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
High-grade gliomas (HGG) are notoriously hard to treat due to surgical limitations and resistance to systemic therapies, resulting in a dire prognosis. Tumor cell motility is a major contributor to treatment failure but simultaneously offers a therapeutic opportunity, utilizing a novel approach called "motility trapping". Motility trapping leverages chemotactic signals to redirect tumor cells to a location where local therapies can target them more effectively. This concept can be applied inward, drawing disseminated tumor cells back to the primary tumor, or outward, guiding them toward a more therapy-accessible location. While preclinical research demonstrates that motility trapping can influence tumor migration, clinical translation remains unestablished. To advance clinical applicability, 4 essential components must be considered: effective migratory stimuli, susceptible tumor cells, suitable delivery systems, and the influence of the tumor microenvironment. For each element, we review current knowledge and propose future directions to develop this innovative approach. In conclusion, redirecting HGG migration through motility trapping offers a transformative strategy that warrants further preclinical and translational investigation. It holds promise to synergize with a plethora of therapeutic strategies that are currently ineffective in brain tumors and should be considered in the design of future therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.